SCHEMBL26075977

SCHEMBL26075977

CCOCCOc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(C)ccc4n3)cc2F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 6/20 0.53
▸ PDE10A Q9Y233 1/20 0.51
▸ KDM4E B2RXH2 5/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ MAPT P10636 5/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ PLA2G2A P14555 2/20 0.46
▸ RARA P10276 1/20 0.45
▸ RARB P10826 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27015272 0.93 DHODH (0.57) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26075296 0.92 KDM4E (0.59) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL23590340 0.92 DHODH (0.56) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26075954 0.92 DHODH (0.52) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26075905 0.91 DHODH (0.56) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26075906 0.90 DHODH (0.55) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26075908 0.90 DHODH (0.55) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26075907 0.90 DHODH (0.55) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL23590263 0.88 DHODH (0.51) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2
SCHEMBL26075911 0.88 DHODH (0.50) DHODHPDE10AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DHODH 1/4885PDE10A 3462/4885KDM4E 1396/4885
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, FAH DHODH 1/4885PDE10A 3672/4885KDM4E 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback